Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 98, Issue 1, 2007, Pages 12-21

  Meltzer, Eli O ^a  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BECLOMETASONE DIPROPIONATE; BENZALKONIUM CHLORIDE; BUDESONIDE; CARBOXYMETHYLCELLULOSE; CICLESONIDE; CISPLATIN; CORTICOSTEROID; DRUG ADDITIVE; DRUG PRESERVATIVE; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; OXYMETAZOLINE; PHENETHYL ALCOHOL; POLYSORBATE; PROPYLENE GLYCOL; RHINARIS; SODIUM CHLORIDE; SORBATE POTASSIUM; SORBITOL; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

AEROSOL; ALLERGIC RHINITIS; BURNING SENSATION; CLINICAL TRIAL; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULARY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRY NOSE; EPISTAXIS; ERYTHEMA; FACE EDEMA; HUMAN; MUCOCILIARY CLEARANCE; NONHUMAN; NOSE DISEASE; NOSE IRRITATION; OSMOTIC PRESSURE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; REVIEW; RHINITIS; SKIN ALLERGY; SKIN IRRITATION; SMELLING DISORDER; SYSTEMATIC REVIEW; TASTE DISORDER; THROAT DISEASE; TREATMENT OUTCOME;

EID: 33846236334     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60854-X     Document Type: Review

References (76)

1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(suppl):S2-S8.
2. Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20:305-317.
3. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001;108:S45-S53.
4. Milgrom H, Bender B. Adverse effects of medications for rhinitis. Ann Allergy Asthma Immunol. 1997;78:439-446.
5. Bousquet J, Van Cauwenberge P, Khaltaev N, ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(suppl 5):S147-S334.
6. Craig TJ, Teets S, Lehman EB, Chinchilli VM, Zwillich C. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol. 1998;101: 633-637.
7. Trangsrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy. 2002;22: 1458-1467.
8. Maibach H, Conant M. Contact urticaria to a corticosteroid cream: polysorbate 60. Contact Dermatitis. 1977;3:350-351.
9. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345:1312-1313.
10. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.
11. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:312-313.
12. Limaye S, Steele RH, Quin J, Cleland B. An allergic reaction to erythropoietin secondary to polysorbate hypersensitivity. J Allergy Clin Immunol. 2002;110:530.
13. Basketter DA, Marriott M, Gilmour NJ, White IR. Strong irritants masquerading as skin allergens: the case of benzalkonium chloride. Contact Dermatitis. 2004;50:213-217.
14. Berg OH, Lie K, Steinsvag SK. The effects of topical nasal steroids on rat respiratory mucosa in vivo, with special reference to benzalkonium chloride. Allergy. 1997;52:627-632.
15. Cureoglu S, Akkus M, Osma U, et al. The effect of benzalkonium chloride on rabbit nasal mucosa in vivo: an electron microscopy study. Eur Arch Otorhinolaryngol. 2002;259: 362-364.
16. Steinsvag SK, Bjerknes R, Berg OH. Effects of topical nasal steroids on human respiratory mucosa and human granulocytes in vitro. Acta Otolaryngol. 1996;116:868-875.
17. Berg OH, Lie K, Steinsvag SK. The effect of decongestive nosedrops on human respiratory mucosa in vitro. Laryngoscope. 1994;104:1153-1158.
18. Bernstein IL. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? a cautionary note based on compromised mucociliary transport. J Allergy Clin Immunol. 2000;105:39-44.
19. Graf P. Benzalkonium chloride as a preservative in nasal solutions: re-examining the data. Respir Med. 2001;95: 728-733.
20. Marple B, Roland P, Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg. 2004;130:131-141.
21. Verret DJ, Marple BF. Effect of topical nasal steroid sprays on nasal mucosa and ciliary function. Curr Opin Otolaryngol Head Neck Surg. 2005;13:14-18.
22. Hofmann T, Gugatschga M, Koidl B, Wolf G. Influence of preservatives and topical steroids on ciliary beat frequency in vitro. Arch Otolaryngol Head Neck Surg. 2004;130:440-445.
23. Riechelmann H, Deutschle T, Stuhlmiller A, Gronau S, Burner H. Nasal toxicity of benzalkonium chloride. Am J Rhinol. 2004; 18:291-299.
24. Stanley PJ, Griffin WM, Wilson R, Greenstone MA, Mackay IS, Cole PJ. Effect of betamethasone and betamethasone with neomycin nasal drops on human nasal mucociliary clearance and ciliary beat frequency. Thorax. 1985;40:607-612.
25. McMahon C, Darby Y, Ryan R, Scadding G. Immediate and short-term effects of benzalkonium chloride on the human nasal mucosa in vivo. Clin Otolaryngol Allied Sci. 1997;22:318-322.
26. Braat J, Ainge G, Bowles JA, et al. The lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: a combined functional, light, scanning and transmission electron microscopy study. Clin Exp Allergy. 1995;25:957-965.
27. Naclerio RM, Baroody FM, Bidani N, De Tineo M, Penney BC. A comparison of nasal clearance after treatment of perennial allergic rhinitis with budesonide and mometasone. Otolaryngol Head Neck Surg. 2003;128:220-227.
28. Graf P, Enerdal J, Hallen H. Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis. Arch Otolaryngol Head Neck Surg. 1999;125:1128-1132.
29. Graf P, Hallen H, Juto JE. Benzalkonium chloride in a decongestant nasal spray aggravates rhinitis medicamentosa in healthy volunteers. Clin Exp Allergy. 1995;25:395-400.
30. Graf P, Hallen H. Effect on the nasal mucosa of long-term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays. Laryngoscope. 1996;106:605-609.
31. Hallen H, Graff P. Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers. Clin Exp Allergy. 1995;25:401-405.
32. Rosenhall L. Evaluation of intolerance to analgesics, preservatives and food colorants with challenge tests. Eur J Respir Dis. 1982;63:410-419.
33. Cho JH, Kwun YS, Jang HS, Kang JM, Won YS, Yoon HR. Long-term use of preservatives on rat nasal respiratory mucosa: effects of benzalkonium chloride and potassium sorbate. Laryngoscope. 2000;110:312-317.
34. Lebe E, Baka M, Yavasoglu A, Aktug H, Ates U, Uyanikgil Y. Effects of preservatives in nasal formulations on the mucosal integrity: an electron microscopic study. Pharmacology. 2004; 72:113-120.
35. Dimova S, Mugabowindekwe R, Willems T, et al. Safety-assessment of 3-methoxyquercetin as an antirhinoviral compound for nasal application: effect on ciliary beat frequency. Int J Pharm. 2003;263:95-103.
36. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665-685.
37. Spector SL, Toshener D, Gay I, Rosenman E. Beneficial effects of propylene and polyethylene glycol and saline in the treatment of perennial rhinitis. Clin Allergy. 1982;12:187-196.
38. Suber RL, Deskin R, Nikiforov I, Fouillet X, Coggins CR. Subchronic nose-only inhalation study of propylene glycol in Sprague-Dawley rats. Food Chem Toxicol. 1989;27:573-583.
39. American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics. 1997;99:268-278.
40. Greenbaum J, Leznoff A, Schulz J, Mazza J, Tobe A, Miller D. Comparative tolerability of two formulations of Rhinalar (flunisolide) nasal spray in patients with seasonal allergic rhinitis. Ann Allergy. 1988;61:305-310.
41. Bennett ML, Fountain JM, McCarty MA, Sherertz EF. Contact allergy to corticosteroids in patients using inhaled or intranasal corticosteroids for allergic rhinitis or asthma. Am J Contact Dermat. 2001;12:193-196.
42. Stafanger G. In vitro effect of beclomethasone dipropionate and flunisolide on the mobility of human nasal cilia. Allergy. 1987; 42:507-511.
43. Eccleston GM, Bakhshaee M, Hudson NE, Richards DH. Rheological behavior of nasal sprays in shear and extension. Drug Dev Ind Pharm. 2000;26:975-983.
44. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol. 2003;117:843-845.
45. Patterson DL, Yunginger JW, Dunn WF, Jones RT, Hunt LW. Anaphylaxis induced by the carboxymethylcellulose component of injectable triamcinolone acetonide suspension (Kenalog). Ann Allergy Asthma Immunol. 1995;74:163-166.
46. Oppliger R, Hauser C. Anaphylaxis after injection of corticosteroid preparations-carboxymethylcellulose as a hidden allergen [in German]. J Dtsch Dermatol Ges. 2004;2:928-930.
47. Mahadevia PJ, Shah S, Leibman C, Kleinman L, O'Dowd L. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis. Ann Allergy Asthma Immunol. 2004;93:345-350.
48. Shah SR, Miller C, Pethick N, Uryniak T, Jones MK, O'Dowd L. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther. 2003;25:2198-2214.
49. Adamopoulos G, Manolopoulos L, Giotakis I. A comparison of the efficacy and patient acceptability of budesonide and beclomethasone dipropionate aqueous nasal sprays in patients with perennial rhinitis. Clin Otolaryngol Allied Sci. 1995;20: 340-344.
50. Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2002;89: 292-297.
51. Meltzer EO, Hadley J, Blaiss M, et al. Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitis. Otolaryngol Head Neck Surg. 2005;132:191-207.
52. Khanna P, Shah A. Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis. Am J Rhinol. 2005;19:316-321.
53. Meltzer EO, Bardelas J, Goldsobel A, Kaiser H. A preference evaluation study comparing the sensory attributes of mometasone furcate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat Respir Med. 2005;4:289-296.
54. Chan H-K, Phipps PR, Gonda I, et al. Regional deposition of nebulized hypodense nonisotonic solutions in the human respiratory tract. Eur Respir J. 1994;7:1483-1489.
55. Katano K, Tsujitani S, Saito H, Ikeguchi M, Maeta M, Kaibara N. Hypotonic intrapleural cisplatin chemotherapy as treatment for pleural carcinomatosis in an experimental model. Anticancer Res. 1997;17:4547-4552.
56. Stephen RL, Novak JM, Jensen EM, Kablitz C, Buys SS. Effect of osmotic pressure on uptake of chemotherapeutic agents by carcinoma cells. Cancer Res. 1990;50:4704-4708.
57. Lee YH, Lee VH. Formulation influence on ocular and systemic absorption of topically applied atenolol in the pigmented rabbit. J Ocul Pharmacol. 1993;9:47-58.
58. Papa V, Aragona P, Russo S, Di Bella A, Russo P, Milazzo G. Comparison of hypotonic and isotonic solutions containing sodium hyaluronate on the symptomatic treatment of dry eye patients. Ophthalmologica. 2001;215:124-127.
59. Boek WM, Keles N, Graamans K, Huizing EH. Physiologic and hypertonic saline solutions impair ciliary activity in vitro. Laryngoscope. 1999;109:396-399.
60. Min YG, Lee KS, Yun JB, et al. Hypertonic saline decreases ciliary movement in human nasal epithelium in vitro. Otolaryngol Head Neck Surg. 2001;124:313-316.
61. Pujara CP, Shao Z, Duncan MR, Mitra AK. Effects of formulation variables on nasal epithelial cell integrity: biochemical evaluations. Int J Pharm. 1995;114:197-203.
62. Dufes C, Olivier J-C, Gaillard F, Gaillard A, Couet W, Muller J-M. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm. 2003;255: 87-97.
63. Yu S, Zhao Y, Wu F, et al. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int J Pharm. 2004;281: 11-23.
64. Shimoda N, Maitani Y, Machida Y, Nagai T. Effects of dose, pH and osmolarity on intranasal absorption of recombinant human erythropoietin in rats. Biol Pharm Bull. 1995;18: 734-739.
65. Olivier J-C, Djilani M, Fahmy S, Couet W. In situ nasal absorption of midazolam in rats. Int J Pharm. 2001;213:187-192.
66. Dua R, Zia H, Needham T. The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits. Int J Pharm. 1997;147:233-242.
67. Nishinaka D, Kishino F, Matsuura A. Water and electrolyte absorption from hypotonic oral rehydration solution in rat small intestine and colon. Pediatr Int. 2004;46:315-321.
68. Wapnir RA, Lifshitz F. Osmolality and solute concentration-their relationship with oral hydration solution effectiveness: an experimental assessment. Pediatr Res. 1985;19:894-898.
69. Wingertzahn MA, Sato H, Nave R, et al. Comparison of nasal tissue concentrations in rabbits following administration of hypotonic and isotonic ciclesonide suspensions [abstract]. J Allergy Clin Immunol. 2005;115(suppl):S126. Abstract 503.
70. Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001;108(suppl):S26-S31.
71. Hallworth GW, Padfreld JM. A comparison of the regional deposition in a model nose of a drug discharged from metered aerosol and metered-pump nasal delivery systems. J Allergy Clin Immunol. 1986;77:348-353.
72. Newman SP, Moren PF, Clarke SW. The nasal distribution of metered dose inhalers. J Laryngol Otol. 1987;101:127-132.
73. Newman SP, Moren F, Clarke SW. Deposition pattern of nasal sprays in man. Rhinology. 1988;26:111-120.
74. Day J, Alexander M, Drouin M, et al. Budesonide aqueous nasal spray and pressurized metered dose inhaler in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol. 1997; 11:77-83.
75. Irander K, Geterud A, Lindqvist N, Pipkorn U. A single blind clinical comparison between 2 preparations of budesonide in the treatment of seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 1984;9:235-241.
76. Aukema AA, Mulder PG, Fokkens WJ. Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery. J Allergy Clin Immunol. 2005;115:1017-1023.